GAITHERSBURG, Md., Sept. 11, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced that it will host its 2nd annual Analyst and Investor Meeting to be held on Tuesday, September 23, 2014 from 9:00 a.m. – 11:00 a.m. (ET) in New York, NY.
Senior management will conduct a series of presentations to update analysts and investors as to the company's recombinant nanoparticle vaccine technology, its RSV program, and its influenza program.
For additional information and registration, please e-mail Novavax@westwicke.com, or call 443-213-0506.
A live webcast link of the presentations will be available via the company website at www.novavax.com under Investor Info/Events. Please allow extra time prior to the webcast to visit the site and download the streaming media software required to listen to the Internet broadcast. The event will be archived on the company's website for 90 days.
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases.
CONTACT: Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000